Our Portfolio
Learn more about our mission-driven companies.
Our Investments
We founded this inflammasome focused company in February 2018 and raised a Series A in February 2020. We have been pleased to work with an excellent management team led by Harlan Weisman and David Barrett. The founders group ended up with approximately 40% of the equity after an initial round of $12mm. Flame completed a $100mm crossover raise in October 2020. The company was sold to Leap Therapeutics in 2023. We have generated a solid return from this investment.
We founded this iNOS inhibition company in November 2023, with a vision to treat breast cancer. Nova’s lead compound is currently being studied in a Phase 1/2 clinical trial and has completed a Phase 1/2 clinical trial in triple negative breast cancer patients. Our stellar team was led by Par S. Hyare and Michael Friedman. In December 2024, Nova was successfully acquired by Galera Therapeutics.
